Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 3
Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC
Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.
Video Player is loading.
Video content above is prompted by the following:
Overall Survival Data from MARIPOSA Trial
Key Themes:
- Significant Survival Improvement: Analysis of the MARIPOSA trial showing amivantamab plus lazertinib leads to improved progression-free survival and overall survival
- Statistical Impact: Overall survival hazard ratio of 0.75 with projected median overall survival exceeding 1 year
- Comparison Considerations: Discussion of MARIPOSA vs FLAURA2 trial designs and outcomes
Notable Insights:
- Dr Dietrich: Called the 12-plus-months overall survival improvement “very refreshing” and noted the “relatively flat trajectory as we move out further on the curve,” indicating durable benefit. He stated, “Breaking through 4 years of overall survival is one thing and...5-year landmark improvements...is also very, very significant.”
- Dr Piotrowska: Emphasized caution when comparing trials, noting that MARIPOSA had “no crossover allowed” while FLAURA2 patients could access chemotherapy in later lines of treatment, making direct comparison of survival outcomes challenging.
Related Content:
